Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$78.00 -0.1%	$76.12	$61.24 ▼ $82.41	$241.88B	0.37	5.09 million shs	1.97 million shs
BMY Bristol Myers Squibb	$46.27 -0.2%	$47.07	$42.96 ▼ $63.33	$94.15B	0.35	12.90 million shs	3.99 million shs
LLY Eli Lilly and Company	$767.58 +2.6%	$740.54	$623.78 ▼ $939.86	$726.05B	0.47	4.09 million shs	2.34 million shs
NVO Novo Nordisk A/S	$57.28 +3.0%	$57.69	$45.05 ▼ $135.20	$255.64B	0.66	11.84 million shs	13.38 million shs
SNY Sanofi	$47.00 +0.8%	$48.61	$44.73 ▼ $60.12	$115.37B	0.51	2.60 million shs	1.05 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	-1.90%	-4.30%	-1.41%	+9.98%	-0.28%
BMY Bristol Myers Squibb	+0.26%	-0.74%	-4.36%	-1.92%	-5.68%
LLY Eli Lilly and Company	-0.88%	+1.31%	+6.66%	-5.48%	-18.99%
NVO Novo Nordisk A/S	+1.24%	+2.43%	+6.08%	-25.22%	-59.40%
SNY Sanofi	-0.87%	-0.38%	-6.33%	-3.32%	-18.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$78.00 -0.1%	$76.12	$61.24 ▼ $82.41	$241.88B	0.37	5.09 million shs	1.97 million shs
BMY Bristol Myers Squibb	$46.27 -0.2%	$47.07	$42.96 ▼ $63.33	$94.15B	0.35	12.90 million shs	3.99 million shs
LLY Eli Lilly and Company	$767.58 +2.6%	$740.54	$623.78 ▼ $939.86	$726.05B	0.47	4.09 million shs	2.34 million shs
NVO Novo Nordisk A/S	$57.28 +3.0%	$57.69	$45.05 ▼ $135.20	$255.64B	0.66	11.84 million shs	13.38 million shs
SNY Sanofi	$47.00 +0.8%	$48.61	$44.73 ▼ $60.12	$115.37B	0.51	2.60 million shs	1.05 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	-1.90%	-4.30%	-1.41%	+9.98%	-0.28%
BMY Bristol Myers Squibb	+0.26%	-0.74%	-4.36%	-1.92%	-5.68%
LLY Eli Lilly and Company	-0.88%	+1.31%	+6.66%	-5.48%	-18.99%
NVO Novo Nordisk A/S	+1.24%	+2.43%	+6.08%	-25.22%	-59.40%
SNY Sanofi	-0.87%	-0.38%	-6.33%	-3.32%	-18.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	2.75	Moderate Buy	$86.00	10.46% Upside
BMY Bristol Myers Squibb	2.24	Hold	$56.38	21.54% Upside
LLY Eli Lilly and Company	2.70	Moderate Buy	$947.39	23.57% Upside
NVO Novo Nordisk A/S	2.24	Hold	$81.00	41.10% Upside
SNY Sanofi	3.20	Buy	$62.67	33.32% Upside

Current Analyst Ratings Breakdown

Latest BMY, AZN, SNY, NVO, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2025	LLY Eli Lilly and Company	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$1,100.00 ➝ $1,050.00
9/16/2025	NVO Novo Nordisk A/S	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy
9/9/2025	NVO Novo Nordisk A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
9/8/2025	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$56.00 ➝ $58.00
9/2/2025	SNY Sanofi	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/22/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2025	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/19/2025	NVO Novo Nordisk A/S	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$105.00 ➝ $70.00
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$56.50B	4.27	$6.16 per share	12.64	$13.18 per share	5.91
BMY Bristol Myers Squibb	$48.30B	1.95	$5.91 per share	7.85	$8.08 per share	5.74
LLY Eli Lilly and Company	$45.04B	16.11	$14.45 per share	53.07	$15.03 per share	51.01
NVO Novo Nordisk A/S	$311.94B	0.82	$4.08 per share	14.06	$4.66 per share	12.32
SNY Sanofi	$44.46B	2.60	$5.33 per share	8.82	$33.20 per share	1.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.66	29.27	15.57	1.46	14.68%	32.84%	12.87%	11/11/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.48	18.69	7.62	2.36	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	49.98	24.64	1.05	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	15.75	12.32	2.08	35.60%	78.64%	24.51%	11/5/2025 (Estimated)
SNY Sanofi	$6.02B	$4.16	11.30	9.90	1.12	21.47%	16.86%	9.63%	10/24/2025 (Estimated)

Latest BMY, AZN, SNY, NVO, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/31/2025	Q2 2025	SNY Sanofi	$0.96	$0.90	-$0.06	$1.84	$9.91 billion	$11.34 billion
7/29/2025	Q2 2025	AZN AstraZeneca	$1.09	$1.09	N/A	$0.79	$14.08 billion	$14.46 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$1.01	1.30%	N/A	37.97%	N/A
BMY Bristol Myers Squibb	$2.48	5.35%	N/A	100.00%	17 Years
LLY Eli Lilly and Company	$6.00	0.78%	N/A	39.22%	11 Years
NVO Novo Nordisk A/S	$0.82	1.43%	N/A	22.53%	N/A
SNY Sanofi	$1.60	3.40%	N/A	38.46%	N/A

Latest BMY, AZN, SNY, NVO, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/29/2025	AZN AstraZeneca	semi-annual	$0.5050	2%	8/8/2025	8/8/2025	9/8/2025
8/6/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.55	0.86	0.67
BMY Bristol Myers Squibb	2.54	1.21	1.11
LLY Eli Lilly and Company	1.86	1.28	1.00
NVO Novo Nordisk A/S	0.52	0.78	0.56
SNY Sanofi	0.19	1.27	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
BMY Bristol Myers Squibb	76.41%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
SNY Sanofi	14.04%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
BMY Bristol Myers Squibb	0.07%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable
SNY Sanofi	82,878	2.46 billion	2.43 billion	Optionable

BMY, AZN, SNY, NVO, and LLY Headlines

Recent News About These Companies

Leerink Partners Maintains a Buy Rating on Sanofi (SNY)

September 15 at 11:00 AM | msn.com

Sanofi (NASDAQ:SNY) Receives $62.67 Consensus Target Price from Analysts

September 15 at 2:13 AM | americanbankingnews.com

9,344 Shares in Sanofi $SNY Purchased by 1248 Management LLC

September 14 at 6:24 AM | marketbeat.com

Integrity Alliance LLC. Invests $706,000 in Sanofi $SNY

September 14 at 4:37 AM | marketbeat.com

Ascent Group LLC Takes $426,000 Position in Sanofi $SNY

September 14 at 4:03 AM | marketbeat.com

Goldman Sachs Group Inc. Lowers Stock Position in Sanofi $SNY

September 14 at 3:45 AM | marketbeat.com

Sanofi (NASDAQ:SNY) Receives Average Rating of "Buy" from Analysts

September 14 at 2:13 AM | marketbeat.com

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

September 11, 2025 | zacks.com

Zimmer Partners LP Sells 126,700 Shares of Sanofi $SNY

September 11, 2025 | marketbeat.com

Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

September 11, 2025 | markets.businessinsider.com

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

September 11, 2025 | globenewswire.com

Sanofi (NASDAQ:SNY) Short Interest Up 35.2% in August

September 10, 2025 | marketbeat.com

Sanofi (NASDAQ:SNY) Upgraded to Overweight at Morgan Stanley

September 10, 2025 | marketbeat.com

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®

September 10, 2025 | prnewswire.com

Sanofi’s Tzield approved in China to delay type 1 diabetes progression

September 10, 2025 | msn.com

Amundi Sells 289,018 Shares of Sanofi $SNY

September 10, 2025 | marketbeat.com

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

September 10, 2025 | globenewswire.com

Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

September 9, 2025 | seekingalpha.com

Positive Report for Sanofi (SNYNF) from Morgan Stanley

September 9, 2025 | theglobeandmail.com

Sanofi (NASDAQ:SNY) Stock Rating Upgraded by Morgan Stanley

September 9, 2025 | americanbankingnews.com

Sanofi upgraded to Overweight from Equal Weight at Morgan Stanley

September 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BMY, AZN, SNY, NVO, and LLY Company Descriptions

AstraZeneca NASDAQ:AZN

$78.00 -0.06 (-0.07%)

As of 02:17 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Bristol Myers Squibb NYSE:BMY

$46.26 -0.09 (-0.18%)

As of 02:17 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Eli Lilly and Company NYSE:LLY

$767.58 +19.39 (+2.59%)

As of 02:17 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$57.28 +1.66 (+2.98%)

As of 02:17 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Sanofi NASDAQ:SNY

$47.00 +0.38 (+0.80%)

As of 02:17 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, AZN, SNY, NVO, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, AZN, SNY, NVO, and LLY Earnings

Compare Dividends

Latest BMY, AZN, SNY, NVO, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, AZN, SNY, NVO, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMY, AZN, SNY, NVO, and LLY Company Descriptions

AstraZeneca NASDAQ:AZN

Bristol Myers Squibb NYSE:BMY

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools